Contralateral axillary lymph node metastasis (CAM) in breast cancer is rare, and the reason is unclear. CAM may be found at the time of primary breast cancer diagnosis or following primary tumor treatment. CAM staging and treatment methods are controversial. Hence, we summarized the features of CAM patients and explored the therapeutic options. We report the case of an 82-year-old woman with right breast cancer accompanied by CAM. The records of breast cancer patients with CAM in PubMed (January 2000-May 2020) were also reviewed. After undergoing comprehensive treatments (neoadjuvant chemotherapy, surgery, radiotherapy, endocrine therapy, and targeted therapy), no signs of recurrence and metastasis were noted during the 25-month follow-up. Overall, 17 studies (36 patients) were selected for the review, of which 15 had synchronous CAM and 21 had metachronous CAM. Nineteen of 22 patients had histologic grade 3. Forty percent (12/30) had ≥4 positive lymph nodes. Among these 36 patients, 9 had triple-negative breast cancers, and 9 were human epidermal growth factor receptor 2 positive. Among the 30 patients staged, 6 (20%) were in stage I; 7 (23.33%), stage II; and 17 (56.67%), stage III. Two patients received systemic therapy, while one received an unknown treatment. The remaining 33 patients all received local treatment (surgery or radiotherapy). The survival time of synchronous and metachronous CAM patients was 12-72 months with the death rate of 1/7 and 12-144 months with that of 3/12, respectively. CAM may be a regional manifestation rather than a distant metastasis. Comprehensive treatment, including surgery and radiotherapy, may provide better control.

乳腺癌对侧腋窝淋巴结转移（CAM）很少见，原因尚不清楚。CAM 可在原发性乳腺癌诊断时或原发性肿瘤治疗后发现。CAM分期和治疗方法存在争议。因此，我们总结了 CAM 患者的特征并探讨了治疗方案。我们报告了一名 82 岁女性患有右侧乳腺癌并伴有 CAM 的病例。还审查了 PubMed（2000 年 1 月至 2020 年 5 月）中患有 CAM 的乳腺癌患者的记录。接受综合治疗（新辅助化疗、手术、放疗、内分泌治疗、靶向治疗）后，随访25个月未见复发转移迹象。总体而言，选择了 17 项研究（36 名患者）进行评价，其中15个有同步CAM，21个有异时CAM。22 名患者中有 19 名组织学分级为 3。40% (12/30) 有≥4 个阳性淋巴结。在这36名患者中，9人患有三阴性乳腺癌，9人为人表皮生长因子受体2阳性。在分期的 30 名患者中，6 名（20%）处于 I 期；7 (23.33%)，第二阶段；和 17 (56.67%)，第三阶段。两名患者接受了全身治疗，而一名患者接受了未知治疗。其余 33 名患者均接受了局部治疗（手术或放疗）。同步和异时CAM患者的生存时间分别为12-72个月，死亡率为1/7，12-144个月，死亡率分别为3/12。CAM 可能是区域表现而非远处转移。综合治疗，包括手术和放疗，